Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2010

DxS to Develop Companion Diagnostic for Pfizer’s Phase II Brain Cancer Candidate

  • The Qiagen subsidiary DxS is to work with Pfizer on the development of a companion diagnostic test kit for the latter’s mid-stage immunotherapy vaccine against glioblastoma (GBM). The aim is to develop a test that can be used routinely to support clinical decision-making.

    The peptide vaccine, designated PF-04948568 (previously known as CDX-110), is currently in Phase II trials in patients with newly diagnosed GBM. PF-04948568 targets the mutated, tumor-specific variant III form of the epidermal growth factor receptor (EGFRvIII), which is present in about 25–40% of tumor vaccines, the companies note. DxS will develop a real-time PCR-based EGFRvIII assay designed to test for the variant in tumor tissue.

    Pfizer acquired worldwide rights to PF-04948568 from CellDex Therapeutics in April 2008; CellDex was previously called Avant Therapeutics. The deal also gives Pfizer exclusive rights to the use of EGFRvIII vaccines in other indications and included a $40 million up-front payment and a $10 million equity investment.

    The company could receive additional milestone fees exceeding $390 million for the successful development and commercialization of PF-04948568 and additional EGFRvIII vaccine products as well as double-digit royalties on any product sales.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »